

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Confirmation Number	5531
Application Number	10/823,834
Filing Date	April 14, 2004
First Named Inventor	Fennimore
Group Art Unit	1615
Examiner Name	C. A. Azpuru
Attorney Docket Number	CRD5078USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/C.A./		BEUTLER, E. "Cladribine (2-chlorodeoxyadenosine)", The Lancet, Vol. 340, p. 952 (October 1992)	
		BREHM, B., et al. "β-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells", Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S401-S403 (2000)	
		BREHM, B., et al. "Chronically Elevated Endothelin-1 Concentrations Modulate the β-Adrenergic Receptor System In Vitro and In Vivo", Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S157-159 (2000)	
		CARSON, D., et al. "DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death", Experimental Cell Research 164 p. 273-281 (1986)	
		CLOWES and SCHWARTZ, "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", Cir. Res. 56: 139-145 (1985)	
		DEROANNE, C., et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular endothelial Growth Factor Signaling", Oncogene 21, p. 427-436 (2002)	
		LANG, R., et al. "Effects of Okadaic Acid and ATPγS on Cell Length and CA ²⁺ - Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", Br. J. Pharmacol. 104, p. 331-336 (1991)	
		SERRUY, P. et al. "Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized double-Blind Placebo-Controlled Trial", Circulation of the Journal of the American Heart Association, 88 p. 1588-1601 (1993)	
✓ /C.A./		SERRUY, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Circulation of the American Heart Association, Volume 93(3) p. 412-422 (1996)	

Examiner Signature	/Carlos Azpuru/	Date Considered	07/08/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Confirmation Number	5531	
Application Number	10/823,834	
Filing Date	April 14, 2004	
First Named Inventor	Fennimore	
Group Art Unit	1615	
Examiner Name	C. A. Azpuru	
Attorney Docket Number	CRD5078USNP	

[illegible]

Examiner Signature	/Carlos Azpuru/	Date Considered	07/08/2009
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.